266 related articles for article (PubMed ID: 3471321)
1. Phase I and clinical pharmacological study of 4-demethoxydaunorubicin (idarubicin) in children with advanced cancer.
Tan CT; Hancock C; Steinherz P; Bacha DM; Steinherz L; Luks E; Winick N; Meyers P; Mondora A; Dantis E
Cancer Res; 1987 Jun; 47(11):2990-5. PubMed ID: 3471321
[TBL] [Abstract][Full Text] [Related]
2. Phase I clinical trial of orally administered 4-demethoxydaunorubicin (idarubicin) with pharmacokinetic and in vitro drug sensitivity testing in children with refractory leukemia.
Pui CH; de Graaf SS; Dow LW; Rodman JH; Evans WE; Alpert BS; Murphy SB
Cancer Res; 1988 Sep; 48(18):5348-52. PubMed ID: 3165708
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of idarubicin hydrochloride in patients with acute leukemia. The Idarubicin Study Group of Japan.
Tamura K
Semin Hematol; 1996 Oct; 33(4 Suppl 3):2-11. PubMed ID: 8916310
[TBL] [Abstract][Full Text] [Related]
4. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report.
Reid JM; Pendergrass TW; Krailo MD; Hammond GD; Ames MM
Cancer Res; 1990 Oct; 50(20):6525-8. PubMed ID: 2208112
[TBL] [Abstract][Full Text] [Related]
5. Phase I and II clinical and pharmacological study of 4-demethoxydaunorubicin (idarubicin) in adult patients with acute leukemia.
Daghestani AN; Arlin ZA; Leyland-Jones B; Gee TS; Kempin SJ; Mertelsmann R; Budman D; Schulman P; Baratz R; Williams L
Cancer Res; 1985 Mar; 45(3):1408-12. PubMed ID: 3855696
[TBL] [Abstract][Full Text] [Related]
6. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
Tedeschi A; Montillo M; Strocchi E; Cafro AM; Tresoldi E; Intropido L; Nichelatti M; Marbello L; Baratè C; Camaggi CM; Morra E
Cancer Chemother Pharmacol; 2007 May; 59(6):771-9. PubMed ID: 17256136
[TBL] [Abstract][Full Text] [Related]
7. Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer.
Tan CT; Hancock CH; Mondora A; Hoffman NW
Cancer Res; 1984 Feb; 44(2):831-5. PubMed ID: 6692381
[TBL] [Abstract][Full Text] [Related]
8. Clinical studies with rubidazone.
Benjamin RS; Keating MJ; Swenerton KD; Legha S; McCredie KB
Cancer Treat Rep; 1979 May; 63(5):925-9. PubMed ID: 287557
[TBL] [Abstract][Full Text] [Related]
9. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
10. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent.
Muus P; Donnelly P; Schattenberg A; Linssen P; Minderman H; Dompeling E; de Witte T
Semin Oncol; 1993 Dec; 20(6 Suppl 8):47-52. PubMed ID: 8290971
[TBL] [Abstract][Full Text] [Related]
11. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
Berman E; Wittes RE; Leyland-Jones B; Casper ES; Gralla RJ; Howard J; Williams L; Baratz R; Young CW
Cancer Res; 1983 Dec; 43(12 Pt 1):6096-101. PubMed ID: 6580068
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of idarubicin given orally in the treatment of anthracycline-naive advanced breast cancer patients.
Bastholt L; Dalmark M
Cancer Treat Rep; 1987 May; 71(5):451-4. PubMed ID: 3471329
[TBL] [Abstract][Full Text] [Related]
13. 4-demethoxydaunorubicin (idarubicin) in combination with 1-beta-D-arabinofuranosylcytosine in the treatment of relapsed or refractory acute leukemia.
Berman E; Raymond V; Daghestani A; Arlin ZA; Gee TS; Kempin S; Hancock C; Williams L; Stevens YW; Clarkson BD
Cancer Res; 1989 Jan; 49(2):477-81. PubMed ID: 2910465
[TBL] [Abstract][Full Text] [Related]
14. [A pharmacokinetic study of idarubicin hydrochloride, a new anthracycline anti-tumor drug, in patients with acute leukemia. Idarubicin Study Group].
Fujita H; Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1992 Jun; 19(6):791-8. PubMed ID: 1605655
[TBL] [Abstract][Full Text] [Related]
15. [A phase I trial of idarubicin by oral administration].
Ogawa M; Kimura K; Taguchi T; Wakui A; Hattori M; Shimoyama T; Fujita H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1896-900. PubMed ID: 3473981
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
17. [Early phase II study of Idarubicin, a new anthracycline anticancer drug, in acute leukemia. Idarubicin Study Group].
Ogawa M; Masaoka T; Yamada K; Kimura K
Gan To Kagaku Ryoho; 1993 May; 20(7):897-906. PubMed ID: 8489296
[TBL] [Abstract][Full Text] [Related]
18. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665
[TBL] [Abstract][Full Text] [Related]
19. A single high dose of idarubicin combined with high-dose ABA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University La Sapienza of Rome.
Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F
Haematologica; 1997; 82(5 Suppl):19-22. PubMed ID: 9402749
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia.
Madon E; Grazia G; De Bernardi B; Comelli A; Carli M; Sainati L; Paolucci G; Canino R; Colella R; Bagnulo S
Cancer Treat Rep; 1987 Sep; 71(9):855-6. PubMed ID: 3476202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]